ABSTRACT
Background Patients admitted to hospital with COVID-19 need rapid identification and isolation to prevent nosocomial transmission. However, isolation facilities are often limited, and SARS-CoV-2 RT-PCR results are often not available when discharged from the emergency department. We evaluated a triage algorithm to isolate patients with suspected COVID-19 using simple clinical criteria and the FebriDx assay.
Design Retrospective observational cohort
Setting Large acute care hospital in London, UK
Participants All medical admissions from the ED between 10th August 2020 and 4th November 2020 with valid SARS-CoV-2 RT-PCR.
Interventions Medical admissions were triaged as likely, possible or unlikely COVID-19 based on clinical criteria. Patients triaged as possible COVID-19 underwent FebriDx lateral flow assay on capillary blood, and those positive for MxA were managed as likely COVID-19.
Primary Outcome measures Diagnostic accuracy (sensitivity, specificity and predictive values) of the algorithm and the FebriDx assay compared to SARS-CoV-2 RT-PCR from nasopharyngeal swabs as the reference standard.
Results 4.0% (136/3,443) of medical admissions had RT-PCR confirmed COVID-19. Prevalence of COVID-19 was 45.7% (80/175) in those triaged as likely, 4.1% (50/1,225) in possible and 0.3% (6/2,033) in unlikely COVID-19. Compared to SARS-CoV-2 RT-PCR, clinical triage had sensitivity of 95.6% (95%CI: 90.5% - 98.0%) and specificity of 61.5% (95%CI: 59.8% - 63.1%), whilst the triage algorithm including FebriDx had sensitivity of 92.6% (95%CI: 86.8% - 96.0%) and specificity of 86.4% (95%CI: 85.2% - 87.5%). The triage algorithm reduced the need for 2,859 patients to be admitted to isolation rooms. Ten patients missed by the algorithm had mild or asymptomatic COVID-19.
Conclusions A triage algorithm including FebriDx assay had good sensitivity and was useful to ‘rule-out’ COVID-19 among medical admissions to hospital.
STRENGTHS AND LIMITATIONS OF THIS STUDY
Pragmatic study including a large cohort of consecutive medical admissions providing routine clinical care.
A single SARS-CoV-2 RT-PCR is an imperfect reference standard for COVID-19. Multiple RT-PCR platforms used, with different PCR targets and performance.
A higher prevalence of COVID-19 or other respiratory pathogens might alter performance.
Criteria for likely and possible COVID-19 groups changed subtly during the study period.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study received no specific grant from any funding agency in the public, commercial or not-for-profit sector. The FebriDx kits were purchased independently from a UK distributer and the manufacturer (Lumos Diagnostics, Sarasota, Florida, USA) had no role in the study conception, design, data analysis or manuscript preparation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the London North West University Hospitals Trust Research and Development Committee, and given this was a retrospective review using routinely collected clinical data, they deemed formal ethical approval was not required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos